The FDA's advertising division said images and copy for the BPH drug Rapaflo are misleading.
CVS will buy institutional pharmacy Omnicare in a $12.7-billion deal; ProPublica says the FDA and GlaxoSmithKline failed to protect patients from misusing Advair; Regeneron and Sanofi expect to file RA drug sarilumab with the FDA in the fourth quarter of this year
The FDA's bad-ad group said the banner they saw at a professional conference was misleading.
McNeil Consumer Healthcare president Denice Torres was named woman of the year by the Healthcare Businesswomen's Association.
Perrigo says a Mylan deal is possible; new guidelines may reduce cancer screenings; Takeda petitions dictionaries to add a new definition for depression
Experts say Afrezza's tepid launch may have more to do with value proposition than product positioning.
Endo agrees to buy Par Pharmaceuticals for $8 billion; AstraZeneca deepens commitment to biologics; FDA cautions that certain diabetes drugs could lead to serious condition
Long-time practice lead Gil Bashe is tasked with unifying and building the health function at global firm Finn Partners.
Genentech alums launch a new biotechnology company; Mallinckrodt sues the FDA over a drug reclassification; Sanofi takes on celiac disease
An expert tells MM&M a key issue is whether unsubstantiated benefits were used in marketing efforts.